Biden hails projected drop in Medicare premiums

Joe Biden, 2020 Democratic presidential nominee, smiles during the first U.S. presidential debate hosted by Case Western Reserve University and the Cleveland Clinic in Cleveland, Ohio, U.S., on Tuesday, Sept. 29, 2020. Trump and Biden kick off their first debate with contentious topics like the Supreme Court and the coronavirus pandemic suddenly joined by yet another potentially explosive question -- whether the president ducked paying his taxes. Photographer: Kevin Dietsch/UPI/Bloomberg
Kevin Dietsch/Bloomberg

President Joe Biden celebrated a drop in premiums for the elderly and disabled on Medicare and lashed out at Republicans for opposing measures he said would also ease the burden on American families.

Speaking at the White House on Tuesday, Biden said the premium cut shows his administration is reducing costs for healthcare services, even though last year's payments were inflated due to costs associated with a new Alzheimer's drug.

"For years, that fee has gone up. Now, for the first time in more than a decade, it's going to go down for millions of seniors and people with disabilities on Medicare," Biden said. "That means more money in their pockets while still getting the care they need."

Elderly and disabled Americans on Medicare will pay less in monthly premiums and deductibles next year as the program has spent less than expected on drugs and other services in 2022, the Department of Health and Human Services said earlier Tuesday.

In his remarks, Biden also touted measures to curb costs in Democrats' massive health, tax and climate package, in particular allowing Medicare to negotiate drug prices for the first time, calling it "a godsend to many families."

The law also capped the out-of-pocket cost of insulin at $35 per month for Medicare beneficiaries, but Republicans blocked a provision that would have extended the cost cap to private insurance. Republicans uniformly opposed the Inflation Reduction Act, which introduced those measures in the House and Senate.

"I wish I could say Republicans supported this progress in reducing health-care costs and strengthening Medicare. That would be good for all Americans, but they have a very different idea," Biden said. "Every single Republican voted against the Inflation Reduction Act when it actually came time to do something about inflation around the kitchen table."

Biden said 158 House Republicans had signed onto a GOP budget that would cut Medicare and Social Security.

"I have a different idea. I'll protect those programs. I'll make them stronger," he said.

Biden has sought to show Americans that his administration is trying to fight inflation, which remains a persistent political liability for Democrats ahead of November's midterm elections. 

On Monday, Biden also convened a meeting of the White House Competition Council, where he criticized airlines and internet-service providers for "hidden fees" and touted proposals to force them to be more transparent about consumer charges.

Alzheimer's coverage
The cut in Medicare premiums follows an unusually large 15% increase in premiums for 2022. About half of that hike — roughly $11 a month per beneficiary — was driven by anticipation that Medicare would have to pay for Biogen's controversial Alzheimer's medication, Aduhelm. Medicare later limited coverage of the drug to people in approved trials, citing unclear evidence of benefit.

Even with the premium cut, seniors will pay more for Medicare coverage than they did two years ago. The standard monthly premium increased from about $149 in 2021 to $170 this year. It will decrease to about $165 for 2023. Individuals earning more than $97,000 a year pay more based on their income. The increase in premiums in 2022 was the largest jump (as measured in dollars) in the program's history, according to AARP.

After Medicare decided in April to restrict coverage of Aduhelm, the Biden administration faced calls to reduce premiums mid-year, but the agency held off until now.

The prospect of new high-cost therapies for common conditions like Alzheimer's has raised concerns about how the program will pay for them. Conflicting data from the Aduhelm trials about whether it slows the course of the disease, along with known risks of side effects, led Medicare to limit reimbursement. More drugs for Alzheimer's are in development, though, and if one with proven benefits reaches the market, it could lead to further premium hikes.

With assistance from Justin Sink.

Bloomberg News
Politics and policy Retirement Medicare
MORE FROM FINANCIAL PLANNING